New 26-week data from the phase 3 COMP006 study validate the long-term durability, safety, and remission potential of a 2-dose COMP360 psilocybin regimen for highly chronic, treatment-resistant ...
High-dose docosahexaenoic acid (DHA) supplementation does not yield a change in brain volume or cognitive performance over 24 months, according to a study publi ...
Those using upadacitinib had lower risk for discontinuing treatment, regardless of previous exposure to treatment ...
Rituximab noninferior to ocrelizumab for suppressing disease activity on T2-weighted MRI between 6 and 24 months.
For most people, the risk for serious muscle disorders from statins is low, according to a study published online June 25 in The Lancet. Ting Cai, DPhil, from t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results